In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.
Emphasizing pixelated detectors and an isotropic spatial resolution upward of 1.25 mm, ultra-high resolution (UHR) brain positron emission tomography (PET) represents a significant advance that provides improved characterization and quantification of brain regions that could not be seen with whole-body PET, noted Roger Lecomte, Ph.D., during a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.
“The spatial resolution is a factor of two better than HRRT (High Resolution Research Tomograph) and a factor of three better than any clinical scanners today. It’s a quantum leap in terms of spatial resolution,” said Dr. Lecomte, a professor of nuclear medicine and radiobiology at the University of Sherbrooke in Quebec, Canada. “To image the brain where you have small structures in the cortex, the brain stem and different regions of the brain, spatial resolution is very important to be able to detect the uptake of radiotracers in very tiny structures.”
One of the areas of improvement with UHR PET imaging was the enhanced visualization of the subfields of the hippocampus that can play a role in the progression of Alzheimer’s disease, according to Vincent Doyon, who presented some of the preliminary findings with UHR PET at the SNMMI conference.
“Depending on how these subfields are affected in the disease, we can see whether treatments are effective for the patient,” added Doyon, a master’s student in the Department of Radiation Sciences and Biomedical Imaging at the University of Sherbrooke.
Donyon added that UHR PET offers enhanced visualization of brainstem nuclei, including raphe nuclei, that may aid in the diagnosis and treatment of a variety of neuropsychiatric conditions, including schizophrenia, depression, and anxiety disorders.
For other insights from Dr. Lecomte and Mr. Doyon, watch the video below.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the